[ET Net News Agency, 15 September 2021] Ocumension Therapeutics (01477) said OT-502
(DEXYCU), one of the group's key drug candidates, was approved by the Center for Drug
Evaluation (CDE) of the National Medical Products Administration of the People's Republic
of China to conduct a phase III clinical trial in China.
It is the first and only FDA-approved, sustained-release intraocular drug for the
treatment of postoperative inflammation indication. (RC)